Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple...

Area of Science:

• Cellular immunotherapy
• Regulatory science
• Oncology drug development

Background:

• Advanced Therapy Medicinal Products (ATMPs) are crucial for treating life-threatening cancers with limited options.
• Current regulatory approaches require continuous evaluation and adjustment to meet the needs of innovative therapies.
• Science and risk-based strategies are essential for managing early clinical research and flexible manufacturing.

Purpose of the Study:

• To explore opportunities for expediting the development of CAR and TCR engineered T cell therapies within the EU regulatory framework.
• To facilitate an iterative and adaptive learning approach across different product versions based on platform technology.
• To identify ways to streamline regulatory submissions and optimize clinical studies.

Main Methods:

• Analysis of the existing EU regulatory framework for ATMPs.
• Exploration of science and risk-based approaches for product development.
• Leveraging iterative and adaptive learning across product versions with similar design elements.

Main Results:

• Opportunities exist to streamline regulatory submissions by extrapolating data across product versions.
• An iterative and adaptive learning approach can reduce the need for duplicative studies.
• Flexible manufacturing paradigms can be balanced with risk mitigation.

Conclusions:

• The T2EVOLVE initiative proposes leveraging the EU regulatory framework to accelerate ATMP development.
• Iterative learning and data extrapolation are key to optimizing clinical studies and submissions.
• Concepts discussed for CAR/TCR T cell therapies may apply to other engineered cell therapies.